ARTICLE | Clinical News
Sepracor starts Phase III trials of (S)-oxybutynin
June 20, 2001 7:00 AM UTC
SEPR started a U.S. Phase III trial of its sustained release formulation of (s)-oxybutynin in 850 patients with overactive bladder. (s)-Oxybutynin is a chirally pure form of oxybutynin, the active ing...